AstraZeneca adds oncolytic virus option through Transgene deal

AstraZeneca is taking another look at oncolytic viruses through an option deal with French biotech Transgene.

On Thursday, the partners said AstraZeneca plc (LSE:AZN; NYSE:AZN) would receive an exclusive option to co-develop and commercialize five armed

Read the full 359 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE